The present disclosure provides a method of restoring immune reconstitution, immune control of viremia, and one or more T cell functions in a subject infected with HIV. The method includes administering to the subject infected with HIV an agent that targets the cofilin pathway.

The present invention pertains to periostin compounds for use in the prevention and treatment of haematological complications, such as adverse events from therapy or haematological diseases. In context of the present invention a therapeutic was developed for enhancing haematopoiesis in patients and to support haematopoietic stem cell (HSC) transplantation (HSCT) by administration of periostin compounds to patients or stem cell donors, or by contacting HSC directly with periostin compounds, for example ex vivo, to improve a transplant HSC preparation. The present invention provides periostin derived compounds such as polypeptides, peptides, nucleic acids, and other periostin-derived agents, that are used both in therapeutic applications and for improving haematopoiesis, for example in stem cell donor subjects or to treat HSC in vitro.

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.

Described are methods and devices for enrichment and in situ expansion of circulating tumor cells (CTCs) from biological samples. The methods may include detecting at least one or more of cell adhesion molecules as epithelial mesenchymal transition (EMT) biomarker. Also described is device for detecting or enriching CTCs. The surface of the device may provide at least one or more of cell binding ligands such as ECM or cadherin derived peptide motif to detect the EMT biomarker. Also described is a surface to remove leukocytes from biological samples, leading to efficient enrichment of CTCs from the biological samples.

The present invention relates to methods that are based on expression of integrin alpha10 and integrin alpha11 on chondrocytes, used for determining purity, quality, degree of chondrocytic identity, chondrocytic potency, and/or degree of chondrocytic phenotype of a composition comprising chondrocytes, as well as for isolating and enriching a population of high quality chondrocytes and controlling culturing and expanding of high quality chondrocytes. The present invention relates also to composition comprising chondrocytes.

The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.

The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.

Provided are methods for making highly dedifferentiated and stem-like human cells from human umbilical vein endothelial cells (HUVECs) ectopically expressing integrin 3. Also provided are methods for making ectoderm, mesoderm, and endoderm cells from HUVECs ectopically expressing integrin 3. Also provided are methods for making neural cells, or cells having neuronal-like morphology, from HUVECs ectopically expressing integrin 3. Provided are methods for making cardiomyocytes, or cells having cardiomyocyte-like morphology, from HUVECs ectopically expressing integrin 3. Provided are methods for the production of pluripotent stem cells comprising expressing integrin 3 in primary human endothelial cells. In alternative embodiments, provided are methods for inducing v3 clustering, and to accelerate or facilitate angiogenesis, tissue remodeling or repair, or wound healing, for example, to accelerate healing after an infarction.

The present application concerns methods for detecting and isolating a population of neural stem cells (NSC) or neural progenitor cells (NPC) based on expression of the marker integrin alpha10beta1; as well as use of said population of NSC or NPC for therapy, diagnosis and prognosis of disease and damage of the CNS.